WO1990011762A1 - 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidin-1-yl)-pyrimidine hydroximinoxidil having antifibroblastic activity - Google Patents
6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidin-1-yl)-pyrimidine hydroximinoxidil having antifibroblastic activity Download PDFInfo
- Publication number
- WO1990011762A1 WO1990011762A1 PCT/EP1990/000542 EP9000542W WO9011762A1 WO 1990011762 A1 WO1990011762 A1 WO 1990011762A1 EP 9000542 W EP9000542 W EP 9000542W WO 9011762 A1 WO9011762 A1 WO 9011762A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- activity
- dihydro
- hydroxy
- hydroxypiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Definitions
- the present invention refers to the use of 6-a ino-l ,2-dihydro-hydroxy-2-imino-( -hydroxypiperidin-l -yDpyridine for the preparation of a medicament having antifibrotic activity useful for the treatment of proliferation conditions of the connective tissue and collagen accumulation.
- Is is known that pathological conditions such as keloids, hypertrophic scars and fibrotic conditions such as scleroderma, are characterized by an excessive proliferation of the connective tissue, whose main component is the finrous protein known as collagen. Said abnormal growth of the connective tissue, taking place also as a consequence of phlogistic processes of various kind (fractures, contusions, distortions, traumas etc.) hinders the physiological processes of tissue repair and healing.
- minoxidil has been studied because of its additional capacity of stimulating hair growth.
- the main pharmacological activity of minoxidil namely the antihypertensive and vasodilating activity, may limit the topical use of the drug, both in the known and widespread treatment of alopecias and in the proposed treatment of fibrotic conditions.
- minoxidil metabolite according to the present invention for the preparation of a medicament having antifibrotic activity is therefore more advantageous in comparison with minoxidil because of possible side-effects that the latter may induce as a consequence • of its vasodilating and antihypertensive activity.
- SKM/101 The new pharmacological activity of the minoxidil metabolite of the invention, hereinafter referred to as SKM/101, was confirmed by inhibition tests of the enzymes prolylhydroxylase and lysylhydroxylase in human skin fibroplasts cultures, according to the method reported in Dermatologica 175(2), 12-18, 1987. A further confirmation was obtained from in vivo tests using guinea-pigs on whose back a silastic valve was implanted, SKM/101 may be formulated in topical phar ⁇ maceutical compositions, using conventional techniques and excipients. Examples of suited pharmaceutical compo- sitions are lotions, creams, ointments, sprays, gauzes, plasters, balsams and the like.
- a particularly convenient administration form consists of lyophilized bovine native collagen, impregnated with SKM/101 or its acceptable salts.
- the concentration of the active principle or of its salts in the above cited pharmaceutical compositions may range from 0.2 to 20% by weight.
- the compositions may also contain other active principles having complementary or anyhow useful activity such as vitamin A or its derivatives, vitamin E or its derivatives, ascorbic acid, glutathion, antioxidants.
- the pharmaceutical compositions of the invention may be administered one or more times a day, according to the pathology to be treated and of the kind of used formulations.
- plasters containing SKM/101 able to release slowly and gradually the active principle are particularly useful.
- SKM/101 may also be administered by local infiltration using known methods, in place of cortison. The following examples further illustrate the invention.
- Vitamine A acetate g 0.20
- Vitamine E acetate g 0.20
- Vitamine C acetate g 0.2
- Each gauze 10 x 10 cm is soaked at saturation with 40 g of a mixture having the following composition: SKM/101 g 2.0 Collagen g 15.0 Glycerine g 10.0
- Vitamine E acetate g 0.2 Purified water q.s, to g 40
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidin-1-yl)pyrimidine is endowed with antifibroblastic activity and may be used for the preparation of a drug useful for treating pathological conditions characterized by proliferation of the connective tissue.
Description
6-amino-l,2-dihydro-l-hydroxy-2-imino-4-(4-hydroxypiperidin -1-yl-pyrimidine hydroxyminoxidil having antifibroblastic activity
The present invention refers to the use of 6-a ino-l ,2-dihydro-hydroxy-2-imino-( -hydroxypiperidin-l -yDpyridine for the preparation of a medicament having antifibrotic activity useful for the treatment of proliferation conditions of the connective tissue and collagen accumulation.
Is is known that pathological conditions such as keloids, hypertrophic scars and fibrotic conditions such as scleroderma, are characterized by an excessive proliferation of the connective tissue, whose main component is the finrous protein known as collagen. Said abnormal growth of the connective tissue, taking place also as a consequence of phlogistic processes of various kind (fractures, contusions, distortions, traumas etc.) hinders the physiological processes of tissue repair and healing.
In the past, pharmacological agents potentially useful for limiting the collagen accumulation in fibrotic conditions have been proposed. Said agents, however, proved to be unsatisfactory because of toxicity problems or lack of specificity. More recently, the inhibiting activity of the fibroplast proliferation and of lysyl hydroxylase of two known anthypertensive drugs, hydralazine and inoxidil, has been described.
Particularly minoxidil has been studied because of its additional capacity of stimulating hair growth. However, the main pharmacological activity of minoxidil, namely the antihypertensive and vasodilating activity,
may limit the topical use of the drug, both in the known and widespread treatment of alopecias and in the proposed treatment of fibrotic conditions.
It has now been found that a metabolite of minoxidil, the 6-amino-l,2-dihydro-l-hydroxy-2-imino-(4- -hydroxypiperidin-l)pyridine already described in the italian patent application nc 22518 A/84 as capable of stimulating the hair growth, shares the antifibroplastic action of minoxidil differing however from the parent molecule in the lack of antihypertensive and vasodilating activity.
The use of the minoxidil metabolite according to the present invention for the preparation of a medicament having antifibrotic activity is therefore more advantageous in comparison with minoxidil because of possible side-effects that the latter may induce as a consequence • of its vasodilating and antihypertensive activity.
The new pharmacological activity of the minoxidil metabolite of the invention, hereinafter referred to as SKM/101, was confirmed by inhibition tests of the enzymes prolylhydroxylase and lysylhydroxylase in human skin fibroplasts cultures, according to the method reported in Dermatologica 175(2), 12-18, 1987. A further confirmation was obtained from in vivo tests using guinea-pigs on whose back a silastic valve was implanted, SKM/101 may be formulated in topical phar¬ maceutical compositions, using conventional techniques and excipients. Examples of suited pharmaceutical compo- sitions are lotions, creams, ointments, sprays, gauzes, plasters, balsams and the like.
A particularly convenient administration form
consists of lyophilized bovine native collagen, impregnated with SKM/101 or its acceptable salts.
The concentration of the active principle or of its salts in the above cited pharmaceutical compositions may range from 0.2 to 20% by weight. The compositions may also contain other active principles having complementary or anyhow useful activity such as vitamin A or its derivatives, vitamin E or its derivatives, ascorbic acid, glutathion, antioxidants. The pharmaceutical compositions of the invention may be administered one or more times a day, according to the pathology to be treated and of the kind of used formulations. For the treatment of keloids, hypertrophic scars, decubitus ulcers and generally facilitating the healing processes, plasters containing SKM/101 able to release slowly and gradually the active principle are particularly useful. SKM/101 may also be administered by local infiltration using known methods, in place of cortison. The following examples further illustrate the invention.
EXAMPLE 1 Lotion
Isopropylmyristate g 1.0 Polyethylenglycol g 2.0
Cetyl alcohol g 2.0
EDTA g 0.05
Ethanol g 15.00
SKM/101 g 10.00 Purified water to ml 100.00
EXAMPLE 2
Lotion
Ethanol g 35.00
Propylen Glycol g 25.00
SKM/101 N-acetyl-cysteine salt g 15.00
Water q.s. • to 100 ml
EXAMPLE 3
Cream
Cetomacrogol g 1.00
Cetostearyl alcohol g 25.00
Glutathion g 0.20
Preserving agent q.s.
Vitamine A acetate g 0.20
SKM/101 g 20.00
Purified water q.s. ml 100.00
EXAMPLE 4
Aerosol
SKM/101 g 2.0
Ethanol g 5.0
Propellant gas g 6.5
EXAMPLE 5
Cream
SKM/101 g 5.0
Polysorbate 80 g 1.0
Spermaceti g 10.0
Propylene glycol g 5.0
Vitamine E acetate g 0.20
Vitamine C acetate g 0.2
P-oxy benzoates g 0.1
Purified water q.s. ml 100
EXAMPLE 6
Gauze
Each gauze 10 x 10 cm is soaked at saturation with 40 g of a mixture having the following composition:
SKM/101 g 2.0 Collagen g 15.0 Glycerine g 10.0
Vitamine E acetate g 0.2 Purified water q.s, to g 40
Claims
1. Use of 6-amino-l,2-dihydro-l-hydroxy-2-amino-(4-hy- droxypiperidin-l-yl)pyridine or of its pharmaceutically acceptable salts for the preparation of a medicament having antifibrotic activity.
2. Topical pharmaceutical compositions containing an effective amount of 6-amino-l,2-dihydro-l-hydroxy-2-ami- no-(4-hydroxypiperidin-l-yl)pyridine or of its pharmaceutically acceptable salts in admixture with an acceptable carrier.
3. Composition according to claim 2 in form of ointments, lotions, plasters, impregnated collagen sheets, gauzes, spray.
4. Compositions according to claim 2 or 3 containing also active principles having complementary or anyhow useful activity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT20126A/89 | 1989-04-13 | ||
| IT8920126A IT1230056B (en) | 1989-04-13 | 1989-04-13 | DERIVATIVE OF 4- (PIPERIDIN-1-IL) PYRIDINE WITH ANTI-FIBROPLASTIC ACTIVITY. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1990011762A1 true WO1990011762A1 (en) | 1990-10-18 |
Family
ID=11164017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1990/000542 Ceased WO1990011762A1 (en) | 1989-04-13 | 1990-04-06 | 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidin-1-yl)-pyrimidine hydroximinoxidil having antifibroblastic activity |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0467908A1 (en) |
| IT (1) | IT1230056B (en) |
| WO (1) | WO1990011762A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986004231A1 (en) * | 1985-01-25 | 1986-07-31 | The Upjohn Company | Pyrimidine sulfates for hair growth |
| GB2183632A (en) * | 1985-12-06 | 1987-06-10 | Kemyos Bio Medical Res | Pyrimidine compounds for the growth of hair and cosmetic formulations containing such compounds |
| EP0242967A1 (en) * | 1986-03-14 | 1987-10-28 | Unilever Plc | Skin treatment composition |
-
1989
- 1989-04-13 IT IT8920126A patent/IT1230056B/en active
-
1990
- 1990-04-06 WO PCT/EP1990/000542 patent/WO1990011762A1/en not_active Ceased
- 1990-04-06 EP EP90905475A patent/EP0467908A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986004231A1 (en) * | 1985-01-25 | 1986-07-31 | The Upjohn Company | Pyrimidine sulfates for hair growth |
| GB2183632A (en) * | 1985-12-06 | 1987-06-10 | Kemyos Bio Medical Res | Pyrimidine compounds for the growth of hair and cosmetic formulations containing such compounds |
| EP0242967A1 (en) * | 1986-03-14 | 1987-10-28 | Unilever Plc | Skin treatment composition |
Non-Patent Citations (4)
| Title |
|---|
| Dermatologica 175, Suppl. 2, 1987, S. Karger AG, (Basel, CH), S.R. PINNELL et al.: "Effects of Minoxidil on Cultured Human Skin Fibroblasts", pages 12-18 * |
| Journal of Biological Chemistry, Volume 262, No. 25, 5 September 1987, The American Society for Biochemistry and Molecular Biology, Inc., (US), S. MURAD et al.: "Suppression of Fibroblast Proliferation and Lysyl Hydroxylase Activity by Minoxidil", pages 11973-11978 * |
| Journal of Pharmaceutical Sciences, Volume 64, No. 8, August 1975, R.C. THOMAS et al.: "Metabolism of Minoxidil, a New Hypotensive Agent II: Biotransformation Following Oral Administration to Rats, Dogs, and Monkeys", pages 1366-1371 * |
| The Merck Index, an Encyclopedia of Chemicals, Drugs, and Biologicals, Tenth Edition, 1983, Merck & Co., Inc., (Rahway, N.J., US), see Abstract No. 6069, "Minoxdil" * |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1230056B (en) | 1991-09-27 |
| EP0467908A1 (en) | 1992-01-29 |
| IT8920126A0 (en) | 1989-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4826830A (en) | Topical application of glyciphosphoramide | |
| US5874444A (en) | Poly (ADP-ribose) polymerase inhibitors to treat diseases associated with cellular senescence | |
| US4141977A (en) | Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds | |
| CA2170016C (en) | Improved method for treating hair loss | |
| CN100420439C (en) | Application of biguanide derivatives in the preparation of medicinal products with scarring effect | |
| JP2004507496A5 (en) | ||
| EP1147086B9 (en) | Compositions for the treatment of skin diseases | |
| EP0387756B1 (en) | Use of 5'-deoxy-5'-methylthioadenosine s-adenosylmethionine and their salts in the preparation of seborrhea-reducing pharmaceutical compositions | |
| US5846552A (en) | Use of 2,4-diaminopyrimidine 3-oxide or a salt thereof for treating collagen maturation and structuring disorders | |
| JPWO1995030412A1 (en) | Cytokine activity enhancer and therapeutic agent for diseases in which cytokine activity is reduced | |
| US5948822A (en) | Treatment of hyperproliferative skin disorders with C18 to C26 alphatic alcohols | |
| KR20050074592A (en) | Method of stimulating hair growth using benzopyrans | |
| JPH07557B2 (en) | Composition for treating dermatitis | |
| KR101792402B1 (en) | Hair growth stimulants comprising nicotinic acid adenine dinucleotide phosphate and its derivatives | |
| WO1990011762A1 (en) | 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-(4-hydroxypiperidin-1-yl)-pyrimidine hydroximinoxidil having antifibroblastic activity | |
| EP0387757A2 (en) | Use of 5'-deoxy-5'methylthioadenosine, S-adenosylmethionine and their salts in the preparation of pharmaceutical compositions favouring hair growth in subjects suffering from baldness | |
| EP0468969A1 (en) | Topical anti-angiogenic as hair growth inhibitors | |
| KR20070097291A (en) | Antibacterial against Propionibacterium acnes | |
| WO1991015210A1 (en) | Compositions comprising cytotoxic agent and permeation enhancers | |
| CN101052400B (en) | Application of pyridine compound for preparing medicine for curing injured skin | |
| GB2263234A (en) | Malotilate for accelerating wound healing | |
| AU779624B2 (en) | Remedies for external use for allergic skin diseases | |
| JP2003246737A (en) | External preparation for skin | |
| US5891881A (en) | Aminoheterocycle-substituted glycerols | |
| JP3193028B2 (en) | External preparation for treating atopic dermatitis containing nitroimidazole compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1990905475 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1990905475 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1990905475 Country of ref document: EP |